Mumbai: It could be before Haffkine Bio Pharmaceutical Corporation countries launched the first batch of covaxin vaccines from their parel facilities.
Working in detail for LABORATORY LEVEL III BIO-SAFETY, it is necessary to make it, it has begun, and the time limit of the laboratory settlement is January 2022, senior official said.
SUBHASH Shankarwar, General Manager of production in Haffkine, said, “Tender has been issued for the construction of this safety laboratory.
The construction can be completed in January.” Laboratories, which will be built under the supervision of ICMR and Haffin scientists, will then be tested for a month.
Haffkkine received permission in April to produce Covaxin through technology transfer from Bharat Biotech producers.
In August, it issued a technical offer for the construction of the BSL III Laboratory.
Previously in a week, Covaxin got a nod from the central committee for emergency use for the age group 2-17.
Haffin plants can play a role in increasing covaxin production.
Haffin officials say technology transfer is a gradual process and will occur gradually.
Shankarwar said after the laboratory was validated, three batch vaccines would be produced and tested for three months.
If everything is fine, vaccine production can be started in April and the vaccine can hit the market in May.
Haffin officials said they could produce 22.8 covaxin crore doses every year.